Charles Sternberg, Associate Editor10.10.22
Société des Céramiques Techniques (SCT Ceramics) has announced a strategic license agreement with Heraeus Deutschland GmbH & Co. KG (Heraeus).
The long-term license grants rights to SCT Ceramics to manufacture and market implantable components and subassemblies, such as hermetic feedthroughs, using Heraeus’ CerMet IP. CerMet is an innovative technology which uses a bio-compatible material system made from aluminum oxide and platinum to achieve ultra-high-density feedthroughs, while lowering production and procurement costs.
Heiko Specht, executive vice president, Global Product and Portfolio Management at Heraeus Medical Components stated, “CerMet represents the excellence, hard work, and diligence of our development teams here at Heraeus Medical Components, and I am excited to see where SCT can take this exciting technology. CerMet addresses a key unmet need in the neuromodulation space for higher channel counts, which opens up many possibilities for innovation. I’m happy to see it transfer to such capable hands and look forward to seeing it improve lives worldwide.”
Jean-Paul Detroyes, president of SCT Ceramics, added, “Our investments in CerMet reflect SCT Ceramics’ commitment of accompanying our customers in their innovative projects. CerMet has promising early results and far-reaching implications for the active implantable medical device market. This is a great addition to our portfolio and will serve as a complementary solution to our brazed product offerings.”
CerMet is a reliable technology which will allow SCT Ceramics to develop high-density feedthroughs with up to 800 channels per square centimeter. High channel counts will allow neuromodulation devices to achieve greater precision, while helping to reduce surface space, a key requirement for devices used in minimally invasive surgeries. SCT Ceramics will take over existing projects and clients related to CerMet, with Heraeus providing training and engineering support during the transition.
The long-term license grants rights to SCT Ceramics to manufacture and market implantable components and subassemblies, such as hermetic feedthroughs, using Heraeus’ CerMet IP. CerMet is an innovative technology which uses a bio-compatible material system made from aluminum oxide and platinum to achieve ultra-high-density feedthroughs, while lowering production and procurement costs.
Heiko Specht, executive vice president, Global Product and Portfolio Management at Heraeus Medical Components stated, “CerMet represents the excellence, hard work, and diligence of our development teams here at Heraeus Medical Components, and I am excited to see where SCT can take this exciting technology. CerMet addresses a key unmet need in the neuromodulation space for higher channel counts, which opens up many possibilities for innovation. I’m happy to see it transfer to such capable hands and look forward to seeing it improve lives worldwide.”
Jean-Paul Detroyes, president of SCT Ceramics, added, “Our investments in CerMet reflect SCT Ceramics’ commitment of accompanying our customers in their innovative projects. CerMet has promising early results and far-reaching implications for the active implantable medical device market. This is a great addition to our portfolio and will serve as a complementary solution to our brazed product offerings.”
CerMet is a reliable technology which will allow SCT Ceramics to develop high-density feedthroughs with up to 800 channels per square centimeter. High channel counts will allow neuromodulation devices to achieve greater precision, while helping to reduce surface space, a key requirement for devices used in minimally invasive surgeries. SCT Ceramics will take over existing projects and clients related to CerMet, with Heraeus providing training and engineering support during the transition.